AAD 2024: scientific presentations supported by Galderma

Galderma, the emerging pure-play dermatology category leader, will be showcasing its innovative, science-based portfolio that spans the full spectrum of the fast-growing dermatology market at the 2024 American Academy of Dermatology Association (AAD) Annual Meeting. Details on scientific presentations supported by Galderma at AAD 2024 can be found below. First author Abstract title and number Presentation time and location Late-breaking presentations J. Silverberg Abstract #56887 Maintenance of efficacy and safety with nemolizumab* at Week 48: results from two global phase III pivotal studies (ARCADIA 1 and ARCADIA 2) in patients with moderate-to-severe atopic dermatitis​ Sunday, March 10, 2024, 2:50 PM PST Upper Level, Room 20BCD S. Kwatra Abstract #56884 Nemolizumab* long-term efficacy and safety up to 52 weeks in the OLYMPIA open-label extension study in patients with prurigo nodularis: an interim analysis Sunday, March 10, 2024, 3:20 PM PST Upper Level, Room 20BCD Oral posters A. Alexis Abstract #53447 Phase IV studies show trifarotene is efficacious and suitable for broad range of patient types Friday, March 8, 2024, 8:35 to 8:40 AM PST Upper Level, Sails Pavilion, Poster Center 1 A. Alexis Abstract #53113 Trifarotene shown to improve acne and related sequelae Friday, March 8, 2024, 9:05 to 9:10 AM PST Upper Level, Sails Pavilion, Poster Center 1 S. Schlessinger Abstract #53083 Efficacy and safety of a novel formulation liquid botulinum toxin, RelabotulinumtoxinA**, when used for combination treatment of glabellar and lateral canthal lines Friday, March 8, 2024, 9:50 to 9:55 AM PST Upper Level, Sails Pavilion, Poster Center 1 C. Whiting Abstract #52929 Primary hyperhidrosis and sensitive skin syndrome: a national pilot survey† Friday, March 8, 2024, 10:10 to 10:15 AM PST Upper Level, Sails Pavilion, Poster Center 1 S.A. Azim Abstract #54376 Sensitive skin: a survey of dermatology resident physicians’ perspectives and educational exposures† Friday, March 8, 2024, 3:50 to 3:55 PM PST Upper Level, Sails Pavilion, Poster Center 1 E-posters J. Manjunath Abstract #52517 Association between prurigo nodularis and cognitive impairment: A retrospective matched cohort study E-posters are accessible online starting Friday, March 8. Meeting attendees may also visit the e-poster viewing stations, located at the Sail Pavilion on the second floor in the San Diego Convention Center J. Cohen Abstract #54283 Upward brow position change after treatment with abobotulinumtoxinA in the glabellar lines R. Siperstein Abstract #49785 Long-term 23-year global post-marketing safety surveillance review of delayed complications with a supportive filler for infraorbital hollow rejuvenation J. Waibel Abstract #52823 A randomized, comparative study describing the gene signatures of poly-L-Lactic acid (PLLA-SCA) and calcium hydroxylapaptite (CaHA) in the treatment of nasolabial folds K.K. Durairaj Abstract #52490 A multi-center, retrospective, chart review to evaluate the safety of poly-L-lactic acid injectable implant when used in non-facial areas Y. Nong Abstract #48854 Treatment with encapsulated benzoyl peroxide leads to a durable shift in the microbiome in rosacea A. Alexis Abstract #51125 Patient exit interviews illustrate benefit of trifarotene on acne-induced pigmentary problems M. Grivet-Seyve Abstract #53537 Sensitive skin syndrome: a meta-analysis of clinical trials evaluating the benefits of dermocosmetics on itch in sensitive skin subjects I. Berlin Abstract #53851 Diverse & inclusive understanding of sensitive skin: A worldwide profiling G. Pellacani Abstract #53019 Efficacy and tolerability of a face serum targeting healthy aging in subjects with sensitive skin N. Joly-Tonetti Abstract #53136 In vitro and in vivo evaluation of a new healthy aging skin care strategy for sensitive skin M. Grivet-Seyve Abstract #54331 Sensitive skin syndrome: a meta-analysis of clinical trials evaluating the impact of dermocosmetics on itch N. Piccardi Abstract #51725 Importance of a tailored skin care routine for patients with moderate acne vulgaris and post-inflammatory hyperpigmentation treated with topical trifarotene T. Nguyen Abstract #53990 Heatmap evaluation of body hydration A. Farberg Abstract #54048 Safety and efficacy of a healing ointment post-surgical wound care T. Nguyen Abstract #54134 A novel 3-step OTC eczema regimen improves eczema severity, itch, and life quality: randomized study All authors are paid consultants or employees of Galderma. * Nemolizumab is an investigational drug and Galderma has not received approval for any indication in any country. ** RelabotulinumtoxinA is an investigational product and has not received approval for any indication in any country. †Posters were developed as part of a Galderma Global Sensitive Skincare Faculty and George Washington University collaboration.

The release as fetched from its publisher. galderma.com ↗